Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer

December 23rd 2024

The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

December 19th 2024

Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.

Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer

December 16th 2024

The EMA’s CHMP has recommended the approval of an expanded indication for dostarlimab plus chemotherapy in primary advanced/recurrent endometrial cancer.

New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward

December 10th 2024

Stephanie Gaillard, MD, PhD, details cervical and ovarian cancer NCCN guideline updates, as well as unmet needs associated with molecular markers.

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer

December 5th 2024

Monica H. Vetter, MD, discusses the integration of immunotherapy into chemotherapy regimens for frontline advanced endometrial cancer.

FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer

December 5th 2024

CRB-701 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.

Cadonilimab Plus Chemotherapy Provides Frontline Survival Benefit in Metastatic Cervical Cancer

December 3rd 2024

Cadonilimab/chemotherapy ± bevacizumab improved survival outcomes vs placebo in frontline persistent, recurrent, or metastatic cervical cancer.

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer

December 3rd 2024

Fruquintinib plus sintilimab injection has received conditional approval from the NMPA for mismatch repair–proficient advanced endometrial cancer.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

November 20th 2024

Alberto Montero, MD, MBA, CPHQ, discusses the potential role for STX-478 in PIK3CA-mutant breast and gynecologic cancers.

Dr Moore on AEs Associated With ADC Treatment in Gynecologic Cancers

November 19th 2024

Kathleen N. Moore, MD, MS, discusses adverse effects associated with the use of antibody-drug conjugates for the treatment of gynecologic cancers.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

November 7th 2024

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

November 7th 2024

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid Tumors

November 5th 2024

Alberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens

November 5th 2024

Experts in gynecologic oncology highlight multiple practice-altering clinical trial updates presented at ESMO and beyond in ovarian, cervical, and endometrial cancers.

Dr Moore on the Evolving Treatment Landscape for Platinum-Resistant Ovarian Cancer

November 4th 2024

Kathleen N. Moore, MD, MS, discusses the evolving landscape in managing platinum-resistant ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 10/27

November 2nd 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

November 1st 2024

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

The OncFive: Top Oncology Articles for the Week of 10/20

October 26th 2024

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer

October 24th 2024

Pembrolizumab-based combinations have been approved in Europe in 2 new indications for endometrial and cervical cancer.